About
Piramidal builds a brain foundation model and real-time EEG copilot that helps neurologists interpret brainwave data, initially for epilepsy diagnosis and later for sleep and cognitive disorders. It sells to neurologists, healthcare institutions, neurotechnology companies, and clinical-trial organizations, differentiating through rapid analysis that reduces EEG review from hours to seconds and aims to reduce manual-review errors.
Market
Piramidal competes in neuroAI, clinical EEG interpretation, neurological diagnostics, and EEG-enabled drug-development markets. Its positioning is broader than traditional point solutions: it is building a general-purpose brain foundation model trained on large and diverse EEG datasets that can be adapted to applications such as epilepsy diagnosis, remote monitoring, and biomarker discovery. Compared with established EEG software and point-of-care platforms, Piramidal differentiates through LLM-like pretraining and fine-tuning, real-time clinical insights, and the ability to scan a full day of EEG data in seconds.
Piramidal primarily targets enterprise healthcare providers—especially hospitals, neurology departments, ICUs, and remote continuous-EEG monitoring companies—with neurologists, epileptologists, and EEG clinicians as core users and buyers. Secondary customers include pharmaceutical and biotechnology companies using EEG for clinical trials, drug discovery, and biomarker development.
At a Glance
Problem
Piramidal targets a bottleneck in neurological diagnosis: EEG data is increasingly collected through remote devices, but neurologists still manually inspect brainwave recordings for abnormal patterns. That review is slow, costly, and error-prone; the company says manual inspection can carry a 30% margin of error, contributing to misdiagnosis and recurrent hospital visits. Its core economic opportunity is to replace hours of specialist review with automated analysis at a fraction of the current cost.
The initial killer use case is epilepsy diagnosis, particularly continuous or remote EEG monitoring. A clinician may need to review a full day of recordings to identify seizures or other abnormalities, so reducing that process from hours to seconds could accelerate intervention while making interpretation more consistent.
Product / Service
Piramidal is building a brain foundation model trained on a large and diverse corpus of electroencephalography data, analogous to how large language models learn from text. The model is intended to be fine-tuned for specialized applications, beginning with a real-time neurologist copilot for epilepsy diagnosis that generates diagnostic insights from a patient’s EEG and standardizes analysis.
The product is being developed as clinical workflow software rather than as a standalone EEG device. Its AI can scan 24 hours of EEG within seconds and is designed to help clinicians identify seizures, strokes, or brain injuries sooner. The company’s partnership with IntraNerve Neuroscience, its first remote-monitoring company partner, is evaluating the tool in a real-world pilot focused on integrating an AI copilot into existing remote EEG workflows.
Market
Piramidal competes in neuroAI, digital neurological diagnostics, and EEG interpretation, with a broader ambition to use one foundation model across diagnosis, drug and biomarker discovery, remote monitoring, sleep and cognitive disorders, and brain-signal applications. A relevant adjacent competitor is Ceribell, whose point-of-care EEG solution triages and continuously monitors patients at risk for seizures; Piramidal’s differentiation is a software foundation-model approach aimed at analyzing diverse EEG data across multiple conditions and settings.
The company has early financing and clinical-validation traction rather than demonstrated scale. It raised a $6 million seed round involving Adverb Ventures, Lionheart Ventures, Y Combinator, and angels, and by April 2026 had announced the IntraNerve partnership and pilot. Y Combinator lists Piramidal as active, founded in 2024, with a 10-person New York City team. The available evidence reports no revenue figure or regulatory clearance, so Piramidal is best characterized as an early-stage company progressing from foundation-model development into clinical workflow validation, not as a proven revenue-scale business.
Founders & Leadership
Funding History
CoreNest
Y Combinator
Recent News
IntraNerve Neuroscience announced a strategic partnership with Piramidal to develop AI technology for analyzing EEG data in critical-care and specialized-monitoring environments. The initiative was being evaluated in a real-world pilot intended to create an AI co-pilot for clinicians monitoring brainwave activity.
Cleveland Clinic described its collaboration with Piramidal to implement a foundational AI model for live, scalable and objective EEG interpretation in inpatient settings. The vendor-agnostic system is designed to analyze 24 hours of EEG data in seconds, with development based on public data and Cleveland Clinic validation work.
The American Hospital Association covered Cleveland Clinic’s partnership with Piramidal to launch an AI model designed to read brainwaves. Piramidal’s tool can scan a full day of EEG data in seconds and is intended to help clinicians identify seizures, strokes and brain injuries sooner.
Axios reported that Cleveland Clinic was teaming up with Piramidal to test an AI model trained to read brainwaves in neurological intensive-care units. The tool can scan a full day of EEG data in seconds, with rollout planned through multiple phases of testing, validation and refinement.
WIRED covered Cleveland Clinic and Piramidal’s development of an AI model trained on brainwave data for monitoring intensive-care patients. The coverage highlights the collaboration’s potential to bring automated brain-activity analysis into ICU care.
Active Roles
2Business Model
Piramidal appears to use a B2B healthcare and neurotechnology model, commercializing EEG analysis and diagnostic tools for neurologists, healthcare institutions, neurotech companies, and clinical-trial organizations. Its materials say the model is offered free for research in exchange for access to EEG records, while commercial users are targeted with analysis at a fraction of current costs; exact pricing or licensing terms are not publicly stated.